Business

Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company

Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company

articleBeijing Hotgen Biotech Co. Ltd. Class AMarch 2, 20263/news/announcement-on-voluntary-disclosure-of-the-completion-of-first-patient-enrollment-and-dosing-in-the-phase-ib-clinical-trial-of-innovative-drug-aa001-monoclonal-antibody-for-alzheimers-disease-by-an-joint-stock-company
Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company

About this update from Beijing Hotgen Biotech Co. Ltd. Class A

Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Beijing Hotgen Biotech Co. Ltd. Class A